Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/β-catenin signaling

Chemico-Biological Interactions

Volumn 181, Issue 2, 2009, Pages 263-271

  Prasad, Chandra P ^a,b   Rath, Gayatri ^a   Mathur, Sandeep ^b   Bhatnagar, Dinesh ^a   Ralhan, Ranju ^b,c,d  

^a SAFDARJUNG HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Curcumin; Cyclin D1; Disheveled; E cadherin; GSK3 ; Slug; Wnt catenin pathway

Indexed keywords

BETA CATENIN; CURCUMIN; CYCLIN D1; DISHEVELLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3; TRANSCRIPTION FACTOR SLUG; UVOMORULIN; WNT PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BETA CATENIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CURCUMIN; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 68849083504     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.06.012     Document Type: Article

References (55)

1. Report of the National Cancer Registry Programme, Ind. Council Med. Res., New Delhi, 2001, 22.
2. Mittra I. Overview of breast cancer in India. Eur. J. Cancer Suppl. 4 (2006) 180
3. Landis-Piwowar K.R., Milacic V., Chen D., Yang H., Zhao Y., Chan T.H., Yan B., and Dou Q.P. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist. Update 9 (2006) 263-273
4. Desai A.G., Qazi G.N., Ganju R.K., El-Tamer M., Singh J., Saxena A.K., Bedi Y.S., Taneja S.C., and Bhat H.K. Medicinal plants and cancer chemoprevention. Curr. Drug Metab. 9 (2008) 581-591
5. Abas F., Hui L.S., Ahmad S., Stanslas J., Israf D.A., Shaari K., and Lajis N.H. Biological evaluation of curcumin and related diarylheptanoids. Z. Naturforsch. 61 (2006) 625-631
6. Anand P., Sundaram C., Jhurani S., Kunnumakkara A.B., and Aggarwal B.B. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 267 (2008) 133-164
7. López-Lázaro M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol. Nutr. Food Res. 52 Suppl. (2008) S103-S127
8. Jagtap S., Meganathan K., Wagh V., Winkler J., Hescheler J., and Sachinidis A. Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr. Med. Chem. 16 (2009) 1451-1462
9. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., Ng C.S., Badmaev V., and Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14 (2008) 4491-4499
10. Lin Y.G., Kunnumakkara A.B., Nair A., Merritt W.M., Han L.Y., Armaiz-Pena G.N., Kamat A.A., Spannuth W.A., Gershenson D.M., Lutgendorf S.K., Aggarwal B.B., and Sood A.K. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin. Cancer Res. 13 (2007) 3423-3430
11. Kawamori T., Lubet R., Steele V.E., Kelloff G.J., Kaskey R.B., Rao C.V., and Reddy B.S. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 59 (1999) 597-601
12. Aggarwal B.B., Kumar A., and Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23 (2003) 363-398
13. Lin J.K. Molecular targets of curcumin. Adv. Exp. Med. Biol. 595 (2007) 227-243
14. Grant S. Co-targeting survival signaling pathways in cancer. J. Clin. Invest. 118 (2008) 3003-3006
15. Azim H., and Azim Jr. H.A. Targeting Her-2/neu in breast cancer: as easy as this!. Oncology 74 (2008) 150-157
16. Fischgräbe J., and Wülfing P. Targeted therapies in breast cancer: established drugs and recent developments. Curr. Clin. Pharmacol. 3 (2008) 85-98
17. Gordon M.D., and Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J. Biol. Chem. 281 (2006) 22429-22433
18. Huang H., and He X. Wnt/beta-catenin signaling: new (and old) players and new insights. Curr. Opin. Cell Biol. 20 (2008) 119-125
19. Wodarz A., and Nusse R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 14 (1998) 59-88
20. Benhaj K., Akcali K.C., and Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol. Rep. 15 (2006) 701-707
21. Ewan K.B., and Dale T.C. The potential for targeting oncogenic WNT/beta-catenin signaling in therapy. Curr. Drug Targets 9 (2008) 532-547
22. Parmalee N.L., and Kitajewski J. Wnt signaling in angiogenesis. Curr. Drug Targets 9 (2008) 558-564
23. Robinson D.R., Zylstra C.R., and Williams B.O. Wnt signaling and prostate cancer. Curr. Drug Targets 9 (2008) 571-580
24. Laux H., Tomer R., Mader M.T., Smida J., Budczies J., Kappler R., Hahn H., Blöchinger M., Schnitzbauer U., Eckardt-Schupp F., Höfler H., and Becker K.F. Tumor-associated E-cadherin mutations do not induce Wnt target gene expression, but affect E-cadherin repressors. Lab Invest. 84 (2004) 1372-1386
25. Ozaki S., Ikeda S., Ishizaki Y., Kurihara T., Tokumoto N., Iseki M., Arihiro K., Kataoka T., Okajima M., and Asahara T. Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol. Rep. 14 (2005) 1437-1443
26. Clifford R.L., Deacon K., and Knox A.J. Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor β1: requirement for Smads, β-catenin and GSK3β. J. Biol. Chem. 283 (2008) 35337-35353
27. Turashvili G., Bouchal J., Burkadze G., and Kolar Z. Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 73 (2006) 213-223
28. Prasad C.P., Gupta S.D., Rath G., and Ralhan R. Wnt signaling pathway in invasive ductal carcinoma of breast: relationship between β-catenin, disheveled and cyclin D1 expression. Oncology 73 (2007) 112-117
29. Prasad C.P., Mirza S., Sharma G., Prashad R., Dattagupta S., Rath G., and Ralhan R. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast. Life Sci. 83 (2008) 318-325
30. Ryo A., Nakamura M., Wulf G., Liou Y.C., and Lu K.P. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat. Cell Biol. 3 (2001) 793-801
31. Huang M., Wang Y., Sun D., Zhu H., Yin Y., Zhang W., Yang S., Quan L., Bai J., Wang S., Chen Q., Li S., and Xu N. Identification of genes regulated by Wnt/beta-catenin pathway and involved in apoptosis via microarray analysis. BMC Cancer 6 (2006) 221
32. Sharma C., Kaur J., Shishodia S., Aggarwal B.B., and Ralhan R. Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology 228 (2005) 1-15
33. Leers M.P., Kölgen W., Björklund V., Bergman T., Tribbick G., Persson B., Björklund P., Ramaekers F.C., Björklund B., Nap M., Jörnvall H., and Schutte B. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 187 (1999) 567-572
34. Cutler W.B. Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cell. Menopause 15 (2008) 1195
35. Kunnumakkara A.B., Anand P., and Aggarwal B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269 (2008) 199-225
36. Pal S., Choudhuri T., Chattopadhyay S., Bhattacharya A., Datta G.K., Das T., and Sa G. Mechanisms of curcumin-induced apoptosis of Ehrlich's ascites carcinoma cells. Biochem. Biophys. Res. Commun. 288 (2001) 658-665
37. Choudhuri T., Pal S., Das T., and Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J. Biol. Chem. 280 (2005) 20059-20068
38. Shishodia S., Singh T., and Chaturvedi M.M. Modulation of transcription factors by curcumin. Adv. Exp. Med. Biol. 595 (2007) 127-148
39. Shao Z.M., Shen Z.Z., Liu C.H., Sartippour M.R., Go V.L., Heber D., and Nguyen M. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int. J. Cancer 98 (2002) 234-240
40. Moiseeva E.P., Almeida G.M., Jones G.D., and Manson M.M. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol. Cancer Ther. 6 (2007) 3071-3079
41. Xia Y., Jin L., Zhang B., Xue H., Li Q., and Xu Y. The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci. 80 (2007) 2161-2169
42. Somers-Edgar T.J., Scandlyn M.J., Stuart E.C., Le Nedelec M.J., Valentine S.P., and Rosengren R.J. The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo. Int. J. Cancer 122 (2008) 1966-1971
43. Sa G., and Das T. Anticancer effects of curcumin: cycle of life and death. Cell Div. 3 (2008) 1-14
44. Park C.H., Hahm E.R., Park S., Kim H.K., and Yang C.H. The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett. 579 (2005) 2965-2971
45. Ryu M.J., Cho M., Song J.Y., Yun Y.S., Choi I.W., Kim D.E., Park B.S., and Oh S. Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem. Biophys. Res. Commun. 377 (2008) 1304-1308
46. Doble B.W., and Woodgett J.R. Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs 185 (2007) 73-84
47. Tomita M., Matsuda T., Kawakami H., Uchihara J.N., Okudaira T., Masuda M., Ohshiro K., and Mori N. Curcumin targets Akt cell survival signaling pathway in HTLV-I-infected T-cell lines. Cancer Sci. 97 (2006) 322-327
48. Schmeiser K., Hammond E.M., Roberts S., and Grand R.J. Specific cleavage of gamma catenin by caspases during apoptosis. FEBS Lett. 433 (1998) 51-57
49. Thompson W.J., Piazza G.A., Li H., Liu L., Fetter J., Zhu B., Sperl G., Ahnen D., and Pamukcu R. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 60 (2000) 3338-3342
50. Mukhopadhyay A., Banerjee S., Stafford L.J., Xia C., Liu M., and Aggarwal B.B. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 21 (2002) 8852-8861
51. Sherr C.J. D-type cyclins. Trends Biochem. Sci. 20 (1995) 187-190
52. Hajra K.M., Chen D.Y., and Fearon E.R. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62 (2002) 1613-1618
53. Li H., Pamukcu R., and Thompson W.J. β-Catenin signaling: therapeutic strategies in oncology. Cancer Biol. Ther. 1 (2002) 621-625
54. Almeida M., Han L., Bellido T., Manolagas S.C., and Kousteni S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J. Biol. Chem. 280 (2005) 41342-41351
55. Luo J.L., Kamata H., and Karin M. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J. Clin. Invest. 115 (2005) 2625-2632